PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 268 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 3.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,596,400 | -21.8% | 182,412 | +2.2% | 0.53% | -17.3% |
| Q2 2023 | $7,153,897 | -3.6% | 178,535 | -1.9% | 0.64% | -6.8% |
| Q1 2023 | $7,423,543 | +110748.8% | 181,905 | +4.9% | 0.69% | +3.1% |
| Q4 2022 | $6,697 | -99.9% | 173,444 | -4.7% | 0.67% | -34.3% |
| Q3 2022 | $9,679,000 | -9.4% | 181,967 | -0.7% | 1.02% | -4.3% |
| Q2 2022 | $10,685,000 | -25.7% | 183,277 | -2.8% | 1.06% | -6.6% |
| Q1 2022 | $14,387,000 | +33.4% | 188,507 | +5.2% | 1.14% | +39.6% |
| Q4 2021 | $10,783,000 | +1.2% | 179,207 | -5.8% | 0.81% | -1.1% |
| Q3 2021 | $10,655,000 | +40.7% | 190,276 | +52.4% | 0.82% | +43.4% |
| Q2 2021 | $7,575,000 | -9.7% | 124,834 | +4.3% | 0.57% | -12.4% |
| Q1 2021 | $8,386,000 | -7.0% | 119,648 | -20.6% | 0.66% | +1.4% |
| Q4 2020 | $9,013,000 | +7.5% | 150,611 | +8.0% | 0.65% | -10.8% |
| Q3 2020 | $8,381,000 | – | 139,403 | – | 0.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |